BCL2 and acute myeloid leukemia: The clinical efficacy of venetoclax in hematologic tumors such as chronic lymphocytic leukemia6,7 and acute myelogenous leukemia (AML)8–11 provides rationale for targeting other prosurvival BCL-2 family proteins.